HHS Seeks Public Input on Overhaul of Federal Vaccine Recommendation Categories

Following a contentious executive order that reduces the scope of universally recommended childhood vaccines, the Department of Health and Human Services (HHS) is soliciting public feedback on the adequacy of the three existing federal vaccine recommendation categories.

The three categories under review are routine, risk‑based, and shared clinical decision‑making. HHS is asking whether to add new categories or modify these existing ones.

The Federal Register notice asks whether the current categories meaningfully differentiate evidence strength, individual and population benefit, and flexibility for personal circumstances and values, and whether they inadvertently suggest that parental permission, individual consent, or clinical discussion applies only to shared clinical decision‑making recommendations.

HHS also proposes introducing additional recommendation categories such as “recommended, but not during infancy,” “recommended with qualification,” and “shared clinical decision‑making with qualification.”

The agency further examines the potential benefits of shared clinical decision‑making—respect for autonomy, informed consent, religious conviction, and individualized clinical judgment—and the possible drawbacks, including confusion, reduced access or uptake, and administrative time burdens.

Richard Hughes IV, J.D., counsel for the American Academy of Pediatrics in its litigation against HHS, commented in an email that the request for information, while presented as an open inquiry, is anything but.

Reading it against the backdrop of the administration’s prior vaccine‑policy actions, Hughes said, it represents the latest step in a predetermined agenda to restructure the federal vaccine recommendation framework, cloaked in the appearance of public input.

He noted that the shared clinical decision‑making category was crafted by the CDC’s Advisory Committee on Immunization Practices over many years of deliberation. “Under the pretense of merely seeking information,” Hughes wrote, “the administration is now signaling its intent to alter existing recommendation categories, or to introduce new ones.”

The notice also raises the possibility of incorporating recommendations from foreign health agencies into U.S. guidance. HHS Secretary Robert F. Kennedy Jr. has previously cited President Donald Trump’s desire to “align the U.S. childhood vaccine schedule with international consensus.”

The document further outlines the factors to be considered when setting vaccine recommendations, stating that commenters are invited to address the availability, quality, and strength of evidence; appropriate approaches when randomized controlled trial evidence is lacking, infeasible, or unethical; disease severity and epidemiology; individual versus population benefit; a presumption favoring individual autonomy, informed consent, and religious freedom; and feasibility and programmatic consequences.

Finally, HHS seeks input on the impact of vaccine mandates and lessons learned from vaccine communication strategies employed during the COVID‑19 pandemic.

The extent to which HHS will incorporate the feedback into policy remains unclear. Comments are due by September 20.

Prominent medical societies, such as the Infectious Diseases Society of America, are expected to submit public comments.

Source link